What is Theravance Biopharma, Inc.'s Market Cap?

Theravance Biopharma, Inc.'s Market Cap is $885.7M, based on as-reported figures from SEC (XBRL) filings.

What is Theravance Biopharma, Inc.'s Trailing P/E?

Theravance Biopharma, Inc.'s Trailing P/E is 16.5×, based on as-reported figures from SEC (XBRL) filings.

What is Theravance Biopharma, Inc.'s Price / Sales?

Theravance Biopharma, Inc.'s Price / Sales is 8.5×, based on as-reported figures from SEC (XBRL) filings.

What is Theravance Biopharma, Inc.'s Revenue (TTM)?

Theravance Biopharma, Inc.'s Revenue (TTM) is $104.3M, based on as-reported figures from SEC (XBRL) filings.

What is Theravance Biopharma, Inc.'s Net Income (TTM)?

Theravance Biopharma, Inc.'s Net Income (TTM) is $53.8M, based on as-reported figures from SEC (XBRL) filings.

What is Theravance Biopharma, Inc.'s EBITDA?

Theravance Biopharma, Inc.'s EBITDA is -$2.7M, based on as-reported figures from SEC (XBRL) filings.

What is Theravance Biopharma, Inc.'s Diluted EPS (TTM)?

Theravance Biopharma, Inc.'s Diluted EPS (TTM) is 1.04, based on as-reported figures from SEC (XBRL) filings.

What is Theravance Biopharma, Inc.'s EBITDA Margin?

Theravance Biopharma, Inc.'s EBITDA Margin is -2.6%, based on as-reported figures from SEC (XBRL) filings.

Theravance Biopharma, Inc. (TBPH) Financial Statements

Theravance Biopharma, Inc.

SIC 2834 · PHARMACEUTICAL PREPARATIONS

FIGI BBG004HK6YY0

XNAS · usd

17.06▼ 0.02 (-0.12%)

As of 2026-09-08

Valuation

Market Cap

Enterprise Value—

Trailing P/E

Price / Sales

EV / Revenue—

EV / EBITDA—

Financial Highlights

Revenue (TTM)

Net Income (TTM)

EBITDA

Diluted EPS (TTM)

EBITDA Margin

Net Debt—

Trading Information

Previous Close17.08

Day's Range17.06 – 17.10

52-Week Range13.08 – 21.03

Volume251.2K

Avg Volume464.4K

Share Statistics

Shares Outstanding

Employees90

ExchangeXNAS

Listed2014-05-16

Share count as of July 31, 2026

ViewDetail

Period

Loading Income Statement…

Key questions about Theravance Biopharma, Inc. (TBPH)

What is Theravance Biopharma, Inc.'s Market Cap?: Theravance Biopharma, Inc.'s Market Cap is $885.7M, based on as-reported figures from SEC (XBRL) filings.
What is Theravance Biopharma, Inc.'s Trailing P/E?: Theravance Biopharma, Inc.'s Trailing P/E is 16.5×, based on as-reported figures from SEC (XBRL) filings.
What is Theravance Biopharma, Inc.'s Price / Sales?: Theravance Biopharma, Inc.'s Price / Sales is 8.5×, based on as-reported figures from SEC (XBRL) filings.
What is Theravance Biopharma, Inc.'s Revenue (TTM)?: Theravance Biopharma, Inc.'s Revenue (TTM) is $104.3M, based on as-reported figures from SEC (XBRL) filings.
What is Theravance Biopharma, Inc.'s Net Income (TTM)?: Theravance Biopharma, Inc.'s Net Income (TTM) is $53.8M, based on as-reported figures from SEC (XBRL) filings.
What is Theravance Biopharma, Inc.'s EBITDA?: Theravance Biopharma, Inc.'s EBITDA is -$2.7M, based on as-reported figures from SEC (XBRL) filings.
What is Theravance Biopharma, Inc.'s Diluted EPS (TTM)?: Theravance Biopharma, Inc.'s Diluted EPS (TTM) is 1.04, based on as-reported figures from SEC (XBRL) filings.
What is Theravance Biopharma, Inc.'s EBITDA Margin?: Theravance Biopharma, Inc.'s EBITDA Margin is -2.6%, based on as-reported figures from SEC (XBRL) filings.